Atrium Therapeutics (Nasdaq: RNA) has earned a USD 15 million development milestone from Bristol Myers Squibb (NYSE: BMY) under their global cardiovascular collaboration, triggered by delivery of the first development candidate for a cardiology indication. The payment marks the first disclosed milestone under a multi-program RNA therapeutic platform licensing deal covering multiple cardiovascular indications.
Under the arrangement, Atrium is eligible to receive up to approximately USD 1.35 billion in research and development milestones, up to approximately USD 825 million in commercial milestones, and tiered royalties reaching into the low double-digits on net sales. BMS funds all future clinical development, regulatory, and commercialization activities arising from the collaboration.
Atrium was formed as a spinout from Avidity Biosciences to advance AOC technology in cardiovascular disease, adapting a platform that has been clinically tested in neuromuscular indications into cardiac tissue. The BMS collaboration is understood to originate from that Avidity-developed technology base, with rights transitioning to Atrium as part of the spinout structure.
The AOC platform combines monoclonal antibody targeting with siRNA-mediated gene silencing, designed to deliver RNA payloads selectively to cardiomyocytes. By using receptor-mediated uptake, the approach aims to overcome limitations seen with lipid nanoparticle delivery systems, which primarily accumulate in the liver. The company also positions the modality as non-viral, potentially enabling repeat dosing—an advantage over adeno-associated virus (AAV)-based gene therapies, which are typically constrained by immune responses.